Abbvie (ABBV) has a debt-to-equity ratio of -11.93, below the Healthcare sector average of 0.3.
Get informed when a big investor buys or sells
+ Follow-11.93
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
Abbvie (ABBV) currently reports a debt-to-equity ratio of -11.93. That is below the Healthcare sector average of 0.3. Use the charts on this page to explore Abbvie's debt-to-equity ratio history and peer comparisons.
Abbvie's debt-to-equity ratio of -11.93 is lower than the Healthcare sector average of 0.3. That is roughly 4125.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The debt-to-equity ratio is a valuation multiple that relates Abbvie's market price to a fundamental measure such as earnings, sales, or book value. At -11.93, ABBV can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current debt-to-equity ratio of -11.93, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.3. From there, open related valuation or income-statement pages for Abbvie, and consider following ABBV for alerts when major investors trade the stock.
Abbvie is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -11.93 versus a sector average near 0.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABBV with unrelated industries.